Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by bigmack1on Mar 15, 2018 1:37pm
286 Views
Post# 27721570

The Run Up

The Run UpMany traders are playing the run up, many are long and aren’t even watching. Some will pile in over the next two days. If the unequivocal superiority of 346 is established and we pass with flying colours, this will most likely be a legendary blue sky breakout. 
I have been here for two years buying and selling, (mostly buying). The risk here is very real and so is the reward. My money is firmly placed on a stellar result! The Antibe team is top notch on all fronts.  Last time during the trial it was discovered that 346 was cleaner and more potent then they thought. That’s why so much effort went into this second attempt. The market over reacted as usual and punished the hell out of our little gem, but when and if we get the wonderful news I am anticipating, it’s all water under the bridge. 
We are through the trial and hold valuable stock in a blockbuster pain medicine! 
For that reason, I am holding hard and strong. The reward outweighs the risk for this guy
Bullboard Posts